Study guide

13.4 Human Identity Testing & Post-Transplant Chimerism

ASCP Molecular Biology Technologist MB

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Strategy

1.1 ASCP MB Exam Structure, Eligibility Routes & Policies 1.2 Computer Adaptive Testing (CAT) & Scoring Mechanics 1.3 Blueprint Navigation & Preparation Strategy

2 Nucleic Acid Chemistry & Molecular Structure

2.1 DNA Structure, Nitrogenous Bases & Thermodynamic Stability 2.2 RNA Types, Secondary Structure & Chemical Lability 2.3 Chromatin Organization, Histone Modifications & DNA Methylation

3 Central Dogma, Genome Organization & Cytogenetics

3.1 DNA Replication Machinery & Enzymology 3.2 Transcription, Translation & Genetic Code 3.3 Mutations, Polymorphisms & Chromosomal Aberrations

4 Biochemical Reagents & Enzymes

4.1 DNA Polymerases, Reverse Transcriptases & Proofreading 4.2 Restriction Endonucleases, Ligases & Nucleases 4.3 Reaction Buffers, Cations & Master Mix Additives

5 Nucleic Acid Isolation & Purification

5.1 Organic & Inorganic Extraction Chemistries 5.2 Solid-Phase Silica Columns & Magnetic Bead Isolation 5.3 Specimen-Specific Lysis & Challenging Matrices

6 Nucleic Acid Quantification & Electrophoresis

6.1 UV Spectrophotometry & Fluorometry 6.2 Agarose & Polyacrylamide Gel Electrophoresis 6.3 Capillary Electrophoresis & Microfluidic Bioanalyzers 6.4 Mass Spectrometry (MALDI-TOF) in Molecular Diagnostics

7 PCR Principles & Primer Design Optimization

7.1 Conventional PCR Thermodynamics & Cycling Kinetics 7.2 Primer Design Criteria, Melting Temp & Secondary Structures 7.3 PCR Inhibition, Facilitators & Troubleshooting

8 Advanced Amplification Technologies

8.1 Real-Time qPCR Probe Chemistries & Fluorescent Dyes 8.2 qPCR Quantification (Standard Curve, ΔΔCt) & Dissociation Melt Curve Analysis 8.3 Digital PCR (dPCR), Droplet Partitioning & Poisson Absolute Quantification 8.4 Isothermal & Target Multiplex Amplification

9 DNA Sequencing Technologies

9.1 Sanger Dideoxy Sequencing & Electropherogram Interpretation 9.2 NGS Library Preparation, Fragmentation & Target Enrichment 9.3 Massively Parallel NGS Platforms & Chemistries 9.4 NGS Quality Metrics, Coverage Depth & Bioinformatics

10 Hybridization, Blotting & Cytogenetic Assays

10.1 Southern, Northern & Dot Blot Chemistries 10.2 Fluorescence In Situ Hybridization (FISH) & CISH 10.3 Microarrays & Array Comparative Genomic Hybridization (aCGH)

11 Molecular Infectious Disease Diagnostics

11.1 Quantitative Viral Load Monitoring (HIV-1, HCV, HBV, CMV) 11.2 Qualitative Multiplex Syndromic Pathogen Panels 11.3 Antimicrobial Resistance Genotyping 11.4 Molecular Epidemiology & Pathogen Typing

12 Molecular Oncology & Hematopathology

12.1 Hematologic Malignancies & Translocation Assays 12.2 Solid Tumor Somatic Driver Mutations 12.3 Microsatellite Instability & DNA Mismatch Repair 12.4 Liquid Biopsy, ctDNA & Minimal Residual Disease

13 Medical Genetics, Pharmacogenomics & Identity Testing

13.1 Single-Gene Mendelian Disorders & CFTR Testing 13.2 Trinucleotide Repeat Expansion Disorders 13.3 Clinical Pharmacogenomics (PGx) Core Alleles 13.4 Human Identity Testing & Post-Transplant Chimerism

14 Quality Assurance, Controls & Method Validation

14.1 Quality Assurance Controls & Reference Materials 14.2 Clinical Method Validation & Performance Characteristics 14.3 Quality Management, Proficiency Testing & Competency

15 Laboratory Operations, Safety & Clinical Variant Reporting

15.1 Physical Facility Design & Unidirectional Workflow 15.2 Laboratory Biosafety, Chemical Hygiene & Waste 15.3 Clinical Calculations, ACMG Variant Classification & HGVS

13.4 Human Identity Testing & Post-Transplant Chimerism

Key Takeaways Explain This Topic AI

Forensic and human identity testing relies on multiplex PCR and capillary electrophoresis of Short Tandem Repeat (STR) tetranucleotide loci from the expanded 20-locus FBI CODIS core panel plus Amelogenin.

Amelogenin genotyping identifies chromosomal sex based on a 6-bp deletion in intron 1 of AMELX (106 bp) versus AMELY (112 bp), yielding a single peak in females (XX) and two peaks (106 bp / 112 bp) in males (XY).

Technical artifacts in capillary electrophoresis STR analysis include stutter (polymerase slippage, N-4 bp), minus-A/incomplete adenylation (split peaks), spectral pull-up, and allelic drop-out/drop-in.

Paternity testing calculates the Paternity Index (PI = X/Y) across independent loci in linkage equilibrium to determine the Combined Paternity Index (CPI) and Probability of Paternity (W = CPI / [CPI + 1]).

Post-allogeneic hematopoietic stem cell transplant (HSCT) monitoring quantifies donor versus recipient chimerism by calculating peak area ratios of informative STR alleles, detecting early relapse or graft failure with a sensitivity of 1-5%.

Last updated: August 2026

13.4 Human Identity Testing & Post-Transplant Chimerism

Quick Summary: Human identity testing, forensic individualization, parentage testing, and post-transplant chimerism analysis exploit hypervariable Short Tandem Repeats (STRs) , also known as microsatellites ( 2 – 6 bp 2–6\text{ bp} 2–6 bp repeat units). The FBI Combined DNA Index System (CODIS) standardizes a core panel of 20 autosomal STR loci plus the Amelogenin ( AMELX/Y ) sex-typing marker. Alleles are amplified in fluorescent multiplex PCR assays and resolved by Capillary Electrophoresis (CE) to within single-base resolution against an allelic ladder. In bone marrow and hematopoietic stem cell transplantation ( HSCT ), STR markers distinguish recipient from donor hematopoiesis to monitor engraftment, mixed chimerism, and early leukemic relapse .

1. Short Tandem Repeats (STRs) & The FBI CODIS Core Loci

Autosomal STR loci are highly polymorphic, non-coding tetranucleotide repeat tracts scattered throughout the human genome that follow Mendelian co-dominant inheritance. +----------------------------------------------------------------------------------------------------+

  • | THE 20 CODIS CORE AUTOSOMAL STR LOCI |
  • +-------------------+-------------------+-------------------+----------------------------------------+
  • | STR Locus Name | Chromosomal Locus | Repeat Motif | Allelic Range & Repeat Characteristics |
  • +-------------------+-------------------+-------------------+----------------------------------------+
  • | **TH01** | **11p15.5** | **[AATG]$_n$** | 5 to 11 repeats; includes microvariant |
  • | | (Intron 1 of *TH*)| | **9.3** (9 full repeats + 3 bp [ATG]) |
  • +-------------------+-------------------+-------------------+----------------------------------------+
  • | **TPOX** | **2p25.3** | **[AATG]$_n$** | 6 to 13 repeats; intron 10 thyroid perox|
  • +-------------------+-------------------+-------------------+----------------------------------------+
  • | **CSF1PO** | **5q33.1** | **[AGAT]$_n$** | 6 to 15 repeats; c-fms proto-oncogene |
  • +-------------------+-------------------+-------------------+----------------------------------------+
  • | **vWA** | **12p13.31** | **[TCTG][TCTA]$_n$| 11 to 24 repeats; von Willebrand gene |
  • +-------------------+-------------------+-------------------+----------------------------------------+
  • | **D3S1358** | **3p21.31** | **[TCTA][TCTG]$_n$| 12 to 19 repeats; complex repeat |
  • +-------------------+-------------------+-------------------+----------------------------------------+
  • | **D8S1179** | **8q24.13** | **[TCTA][TCTG]$_n$| 8 to 19 repeats; complex repeat |
  • +-------------------+-------------------+-------------------+----------------------------------------+
  • | **D21S11** | **21q21.1** | **Complex tetra** | 24 to 38 repeats; complex microvariants|
  • +-------------------+-------------------+-------------------+----------------------------------------+
  • | **FGA** | **4q31.3** | **[CTTT]$_n$** | 17 to 30+ repeats; alpha-fibrinogen |
  • +-------------------+-------------------+-------------------+----------------------------------------+
  • | **Additional 12 | D1S1656, D2S441, D2S1338, D5S818, D7S820, D10S1248, D12S391, D13S317, |
  • | CODIS Loci** | D16S539, D18S51, D19S433, D22S1045; plus optional Penta D, Penta E |
  • +-------------------+-------------------+-------------------+----------------------------------------+
  • Amelogenin Sex Determination Assay

The Amelogenin gene ( AMELX on Xp22.2; AMELY on Yp11.2) is not an STR, but a sequence-conserved gene used in identity testing to establish biological sex:

Structure : Intron 1 of AMELX harbors a 6-bp deletion (positions 106 bp) relative to the homologous region in AMELY (112 bp).

Females ( X X XX XX ) : Produce a single fluorescent peak at 106 bp 106\text{ bp} 106 bp (homozygous X X X ).

Males ( X Y XY X Y ) : Produce two fluorescent peaks at 106 bp 106\text{ bp} 106 bp and 112 bp 112\text{ bp} 112 bp with an approximately equal 1 : 1 1:1 1 : 1 peak height ratio.

Technical Caveat : Rare phenotypic males with a deletion of the AMELY locus on Yp11.2 can type falsely as female (single 106 bp peak); resolved by testing male-specific Y-STR markers (e.g., DYS19 , DYS389I/II , DYS390 ). AMELOGENIN CAPILLARY ELECTROPHEROGRAM

  • [ Female Profile (XX) ] [ Male Profile (XY) ]
  • Fluorescence Fluorescence
  • ^
  • | || | || ||
  • | || (106 bp) | || (106 bp) || (112 bp)
  • | || | || ||
  • +--------+-----------------> Size +--------+-----------+------> Size
  • 2. Technical Artifacts in STR Capillary Electrophoresis

Accurate interpretation of STR electropherograms requires distinguishing true biological alleles from in vitro enzymatic and optical artifacts. +----------------------------------------------------------------------------------------------------+

  • | TECHNICAL ARTIFACTS IN CAPILLARY ELECTROPHORESIS |
  • +-------------------+-------------------+-------------------+----------------------------------------+
  • | Artifact Type | Molecular Cause | Peak Characteristics| Laboratory Remediation Strategy |
  • +-------------------+-------------------+-------------------+----------------------------------------+
  • | **Stutter** | DNA polymerase | Minor peak **one | Filter using locus-specific stutter |
  • | | slippage during | repeat unit shorter| thresholds (typically $\le 15\%$ of |
  • | | in vitro PCR | ($-4\text{ bp}$)**| true parent peak height) |
  • +-------------------+-------------------+-------------------+----------------------------------------+
  • | **Split Peaks / | Incomplete non- | True amplicon ($N$)| Perform an extended post-PCR terminal |
  • | Minus-A (-A)** | templated adenine | alongside adenyl- | incubation ($60–72^\circ\text{C}$ for |
  • | | addition by Taq | ated form ($N+1$),| $30–60\text{ min}$) to force 100% $+A$ |
  • | | | $1\text{ bp}$ apart| conversion |
  • +-------------------+-------------------+-------------------+----------------------------------------+
  • | **Pull-Up / | Incomplete matrix | Phantom peak at | Re-run spectral matrix calibration; |
  • | Bleed-Through** | deconvolution; | identical base-pair| dilute overloaded amplicon to reduce |
  • | | excessive signal | size in an adjacent| fluorescent saturation |
  • | | (>8,000 RFU) | dye channel | |
  • +-------------------+-------------------+-------------------+----------------------------------------+
  • | **Allelic | Stochastic low- | Complete loss of | Increase template input ($>0.5–1\text{ ng}$);|
  • | Drop-Out** | template sampling | one true allele in| redesign primers if binding site |
  • | | or primer mutation| a heterozygote | polymorphism is suspected |
  • +-------------------+-------------------+-------------------+----------------------------------------+
  • | **Microvariants** | Incomplete repeat | Real biological | Aligns precisely to designated decimal |
  • | (Off-Ladder)** | units (e.g., TH01 | allele (e.g., 9.3)| bins in allelic ladder; verified by |
  • | | 9.3 = 9x + 3 bp) | | re-injection or sequencing |

+-------------------+-------------------+-------------------+----------------------------------------+ ELECTROPHEROGRAM ARTIFACT PROFILES

[ Stutter Artifact ] [ Minus-A Split Peak ] [ Pull-Up / Bleed-Through ]

Fluorescence Fluorescence FAM Channel (Blue Overload):

  • ^ ^
  • | || (True Peak) | || (N+1 Form) | ||||| (>8000 RFU)

| | || | || || (N Form) VIC Channel (Green Pull-Up):

  • | | || | || || |
  • +---+---+--------> +---+---+--------> | | (Phantom Peak!)
  • N-4 N N N+1 +-------+--------------->
  • 3. Paternity Index & Probability of Paternity Calculations

In parentage testing, genetic markers are evaluated to determine whether an alleged father (AF) can be excluded from biological paternity, or to calculate the statistical weight of inclusion.

Direct Exclusion Criteria

Direct Exclusion (Class I) : The child possesses an obligate paternal allele that is absent in both the biological mother and the alleged father (e.g., Mother: 12 , 12 12, 12 12 , 12 ; Child: 12 , 14 12, 14 12 , 14 ; Obligate Paternal Allele = 14 14 14 ; Alleged Father: 10 , 11 10, 11 10 , 11 ).

Exclusion Standard : Modern legal standards require direct exclusions at ≥ 2 – 3 \ge 2–3 ≥ 2–3 independent STR loci to confirm non-paternity, preventing a false exclusion caused by a sporadic single-locus germline mutation.

Statistical Paternity Index Formula

The Paternity Index ( P I PI P I ) at an individual locus represents the likelihood ratio comparing the probability of observing the child's genotype if the alleged father is the biological father ( X X X ) versus if a random unrelated man from the population is the father ( Y Y Y ): P I = X Y PI = \frac{X}{Y} P I = Y X ​

If the Alleged Father is homozygous for the obligate paternal allele: X = 1.0 X = 1.0 X = 1.0 ; P I = 1.0 p PI = \frac{1.0}{p} P I = p 1.0 ​

If the Alleged Father is heterozygous for the obligate paternal allele: X = 0.5 X = 0.5 X = 0.5 ; P I = 0.5 p PI = \frac{0.5}{p} P I = p 0.5 ​ (where p p p is the population frequency of the obligate paternal allele). Combined Paternity Index (CPI) = P I 1 × P I 2 × P I 3 × ⋯ × P I n \text{Combined Paternity Index (CPI)} = PI_1 \times PI_2 \times PI_3 \times \dots \times PI_n Combined Paternity Index (CPI) = P I 1 ​ × P I 2 ​ × P I 3 ​ × ⋯ × P I n ​ Probability of Paternity ( W ) = C P I × P 0 ( C P I × P 0 ) + ( 1 − P 0 ) × 100 % \text{Probability of Paternity } (W) = \frac{CPI \times P_0}{(CPI \times P_0) + (1 - P_0)} \times 100\% Probability of Paternity ( W ) = ( CP I × P 0 ​ ) + ( 1 − P 0 ​ ) CP I × P 0 ​ ​ × 100%

Assuming a neutral prior probability ( P 0 = 0.5 P_0 = 0.5 P 0 ​ = 0.5 ), the equation simplifies to: W = C P I C P I + 1 × 100 % W = \frac{CPI}{CPI + 1} \times 100\% W = CP I + 1 CP I ​ × 100%

(A C P I ≥ 100 CPI \ge 100 CP I ≥ 100 corresponds to W ≥ 99.0 % W \ge 99.0\% W ≥ 99.0% , and C P I ≥ 10 , 000 CPI \ge 10,000 CP I ≥ 10 , 000 achieves legal proof of paternity with W ≥ 99.99 % W \ge 99.99\% W ≥ 99.99% ).

4. Post-Allogeneic Stem Cell Transplant Chimerism Monitoring

Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative therapy for leukemias, lymphomas, and marrow failure disorders. Post-transplant chimerism testing quantifies the proportion of donor versus recipient cells in the host bone marrow or peripheral blood. +----------------------------------------------------------------------------------------------------+

  • | CHIMERISM STATUS DEFINITIONS |
  • +-------------------+-------------------+------------------------------------------------------------+
  • | Chimerism State | % Donor Hematopoiesis| Clinical Interpretation & Management |
  • +-------------------+-------------------+------------------------------------------------------------+
  • | **Complete / Full | **100% Donor** | **Successful Engraftment**: Complete eradication of |
  • | Chimerism** | ($<1\%$ Recipient)| recipient marrow; minimal risk of immediate relapse |
  • +-------------------+-------------------+------------------------------------------------------------+
  • | **Mixed | **1% to 99% Donor**| **Coexistence of Donor & Host**: May be stable (tolerance) |
  • | Chimerism** | | or progressive (impending graft rejection or relapse) |
  • +-------------------+-------------------+------------------------------------------------------------+
  • | **Split-Lineage / | Variable across | Evaluates purified fractions: **CD3+ T-cells**, |
  • | Lineage-Specific**| T, B, & Myeloid | **CD19+ B-cells**, and **CD33+/CD15+ Myeloid cells** |
  • +-------------------+-------------------+------------------------------------------------------------+
  • | **Graft Failure / | **< 1% Donor** | **Rejection / Relapse**: Complete loss of donor cells with |
  • | Rejection** | (>99% Recipient) | autologous host marrow reconstitution or leukemic recurrence|

+-------------------+-------------------+------------------------------------------------------------+ INFORMATIVE STR LOCUS PROFILES

  • [ Fully Informative Locus ] [ Partially Informative Locus ]
  • Recipient: Alleles 12, 14 Recipient: Alleles 10, 12
  • Donor: Alleles 10, 11 Donor: Alleles 10, 14
  • (All peaks distinct and non-shared!) (Allele 10 is shared; 12 and 14 are unique)
  • Fluorescence Fluorescence
  • ^ ^
  • | || || || || | || || ||
  • | || || || || | || (Shared) || (Recip) || (Donor)
  • +----+-------+------+-------+-----> +----+-----------+-----------+----->
  • D:10 D:11 R:12 R:14 10 12 14
  • 5. Quantitative Chimerism Calculations & Lineage Sorting
  • Peak Area Chimerism Formula

For an informative STR locus displaying distinct recipient-specific ( R 1 , R 2 R_1, R_2 R 1 ​ , R 2 ​ ) and donor-specific ( D 1 , D 2 D_1, D_2 D 1 ​ , D 2 ​ ) peaks: % Recipient DNA = ( ∑ Area Recipient Unique Peaks ∑ Area Recipient Unique Peaks + ∑ Area Donor Unique Peaks ) × 100 % \%\text{ Recipient DNA} = \left( \frac{\sum \text{Area}_{\text{Recipient Unique Peaks}}}{\sum \text{Area}_{\text{Recipient Unique Peaks}} + \sum \text{Area}_{\text{Donor Unique Peaks}}} \right) \times 100\% % Recipient DNA = ( ∑ Area Recipient Unique Peaks ​ + ∑ Area Donor Unique Peaks ​ ∑ Area Recipient Unique Peaks ​ ​ ) × 100% % Donor DNA = 100 % − % Recipient DNA \%\text{ Donor DNA} = 100\% - \%\text{ Recipient DNA} % Donor DNA = 100% − % Recipient DNA +----------------------------------------------------------------------------------------------------+

  • | LINEAGE-SPECIFIC CELL SORTING IN POST-TRANSPLANT HSCT |
  • +-------------------+-------------------+-------------------+----------------------------------------+
  • | Cell Population | Surface Marker | Isolation Method | Clinical Value & Diagnostic Utility |
  • +-------------------+-------------------+-------------------+----------------------------------------+
  • | **T-Lymphocytes** | **CD3+** | Magnetic Bead | Assesses **graft-versus-host / graft- |
  • | | (Pan T-cell) | (MACS) or FACS | versus-leukemia (GvL)** potential; pre-|
  • | | | | dicts early graft rejection |
  • +-------------------+-------------------+-------------------+----------------------------------------+
  • | **Myeloid Cells** | **CD33+ / CD15+ / | Magnetic Bead | Detects **early acute myeloid leukemia |
  • | | CD14+** | (MACS) or FACS | (AML) relapse**; myeloid cells have |
  • | | | | short half-life ($<24\text{ hrs}$) |
  • +-------------------+-------------------+-------------------+----------------------------------------+
  • | **B-Lymphocytes** | **CD19+ / CD20+** | Magnetic Bead | Monitors B-ALL recurrence and post- |
  • | | | (MACS) or FACS | transplant lymphoproliferative disorder|

+-------------------+-------------------+-------------------+----------------------------------------+ +----------------------------------------------------------------------------------------------------+

  • | CHIMERISM TESTING PLATFORMS COMPARISON |
  • +-------------------+-------------------+-------------------+----------------------------------------+
  • | Methodology | Limit of Detection| Quantitative Range| Key Strengths & Technical Trade-Offs |
  • +-------------------+-------------------+-------------------+----------------------------------------+
  • | **STR-PCR with | **1.0% to 5.0%** | 1% to 100% | Standard, cost-effective, multiplexed; |
  • | Capillary Elect.**| | | lacks sensitivity for deep MRD |
  • +-------------------+-------------------+-------------------+----------------------------------------+
  • | **Droplet Digital | **0.01% to 0.1%** | 0.01% to 100% | Absolute Poisson quantification; |
  • | PCR (ddPCR)** | | | highly sensitive for early host relapse|
  • +-------------------+-------------------+-------------------+----------------------------------------+
  • | **Targeted NGS | **0.05% to 0.1%** | 0.05% to 100% | Simultaneous profiling of hundreds of |
  • | SNP Panels** | | | informative SNPs; high throughput |
  • +-------------------+-------------------+-------------------+----------------------------------------+

Loading diagram... Post-Transplant Chimerism Monitoring and Lineage-Specific Fractionation Workflow